LGND vs. ELAN

Last updated Apr 1, 2026

Compare and contrast key facts about Ligand Pharmaceuticals Incorporated (LGND) and Elanco Animal Health Incorporated (ELAN).

Performance

LGND vs. ELAN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ligand Pharmaceuticals Incorporated (LGND) and Elanco Animal Health Incorporated (ELAN). The values are adjusted to include any dividend payments, if applicable.

LGND vs. ELAN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
LGND Ligand Pharmaceuticals Incorporated	5.60%	76.45%	50.03%	6.92%	-56.75%	55.31%	-4.64%	-23.15%	-47.36%
ELAN Elanco Animal Health Incorporated	5.74%	86.87%	-18.72%	21.93%	-56.94%	-7.47%	4.14%	-6.60%	-12.42%

Fundamentals

Market Cap LGND : $4.22B ELAN : $11.89B
EPS LGND : $6.10 ELAN : -$0.47
PS Ratio LGND : 15.20 ELAN : 2.53
PB Ratio LGND : 4.15 ELAN : 1.82
Total Revenue (TTM) LGND : $268.09M ELAN : $4.72B
Gross Profit (TTM) LGND : $175.85M ELAN : $2.59B
EBITDA (TTM) LGND : $143.43M ELAN : $874.00M

Returns By Period

The year-to-date returns for both investments are quite close, with LGND having a 5.60% return and ELAN slightly higher at 5.74%.

LGND

• 1D: 3.64%
• 1M: 0.68%
• YTD: 5.60%
• 6M: 12.71%
• 1Y: 89.89%
• 3Y*: 39.49%
• 5Y*: 5.25%
• 10Y*: 6.06%

ELAN

• 1D: 2.09%
• 1M: -9.36%
• YTD: 5.74%
• 6M: 18.82%
• 1Y: 127.90%
• 3Y*: 36.54%
• 5Y*: -3.63%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LGND vs. ELAN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LGND

LGND Risk / Return Rank: 94
LGND Sharpe Ratio Rank: 95
LGND Sortino Ratio Rank: 93
LGND Omega Ratio Rank: 90
LGND Calmar Ratio Rank: 96
LGND Martin Ratio Rank: 95

ELAN

ELAN Risk / Return Rank: 95
ELAN Sharpe Ratio Rank: 94
ELAN Sortino Ratio Rank: 96
ELAN Omega Ratio Rank: 94
ELAN Calmar Ratio Rank: 94
ELAN Martin Ratio Rank: 97

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LGND vs. ELAN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ligand Pharmaceuticals Incorporated (LGND) and Elanco Animal Health Incorporated (ELAN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LGND	ELAN	Difference
Sharpe ratio Return per unit of total volatility	2.61	2.54	+0.07
Sortino ratio Return per unit of downside risk	3.24	3.65	-0.41
Omega ratio Gain probability vs. loss probability	1.40	1.47	-0.07
Calmar ratio Return relative to maximum drawdown	6.48	5.24	+1.24
Martin ratio Return relative to average drawdown	15.70	19.72	-4.02
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LGND vs. ELAN - Sharpe Ratio Comparison

The current LGND Sharpe Ratio is 2.61, which is comparable to the ELAN Sharpe Ratio of 2.54. The chart below compares the historical Sharpe Ratios of LGND and ELAN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LGND	ELAN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.61	2.54	+0.07
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.12	-0.08	+0.20
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.13	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.10	-0.12	+0.22

Correlation

The correlation between LGND and ELAN is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LGND vs. ELAN - Dividend Comparison

Neither LGND nor ELAN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

LGND vs. ELAN - Drawdown Comparison

The maximum LGND drawdown since its inception was -93.34%, which is greater than ELAN's maximum drawdown of -78.00%. Use the drawdown chart below to compare losses from any high point for LGND and ELAN.

Drawdown Indicators

	LGND	ELAN	Difference
Max Drawdown Largest peak-to-trough decline	-93.34%	-78.00%	-15.34%
Max Drawdown (1Y) Largest decline over 1 year	-13.21%	-24.79%	+11.58%
Max Drawdown (5Y) Largest decline over 5 years	-70.11%	-78.00%	+7.89%
Max Drawdown (10Y) Largest decline over 10 years	-81.94%	—	—
Current Drawdown Current decline from peak	-27.27%	-34.83%	+7.56%
Average Drawdown Average peak-to-trough decline	-44.71%	-39.85%	-4.86%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.45%	6.59%	-1.14%

Volatility

LGND vs. ELAN - Volatility Comparison

The current volatility for Ligand Pharmaceuticals Incorporated (LGND) is 11.92%, while Elanco Animal Health Incorporated (ELAN) has a volatility of 14.67%. This indicates that LGND experiences smaller price fluctuations and is considered to be less risky than ELAN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LGND	ELAN	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.92%	14.67%	-2.75%
Volatility (6M) Calculated over the trailing 6-month period	24.57%	25.64%	-1.07%
Volatility (1Y) Calculated over the trailing 1-year period	34.70%	50.67%	-15.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	43.98%	44.53%	-0.55%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	45.12%	43.81%	+1.31%

Financials

LGND vs. ELAN - Profitability Comparison

The chart below illustrates the profitability comparison between Ligand Pharmaceuticals Incorporated and Elanco Animal Health Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

LGND - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Ligand Pharmaceuticals Incorporated reported a gross profit of 0.00 and revenue of 59.67M. Therefore, the gross margin over that period was 0.0%.

ELAN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Elanco Animal Health Incorporated reported a gross profit of 853.00M and revenue of 1.14B. Therefore, the gross margin over that period was 74.6%.

LGND - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Ligand Pharmaceuticals Incorporated reported an operating income of 13.84M and revenue of 59.67M, resulting in an operating margin of 23.2%.

ELAN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Elanco Animal Health Incorporated reported an operating income of 562.00M and revenue of 1.14B, resulting in an operating margin of 49.1%.

LGND - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Ligand Pharmaceuticals Incorporated reported a net income of 44.78M and revenue of 59.67M, resulting in a net margin of 75.1%.

ELAN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Elanco Animal Health Incorporated reported a net income of -276.00M and revenue of 1.14B, resulting in a net margin of -24.1%.